Outcome Measures of Chinese Herbal Medicine for Coronary Heart Disease: An Overview of Systematic Reviews by Luo, Jing & Xu, Hao
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 927392, 9 pages
doi:10.1155/2012/927392
Review Article
Outcome Measures of Chinese Herbal Medicine for Coronary
HeartDisease:An OverviewofSystematic Reviews
Jing Luo1,2 andHaoXu2
1Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
2Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
Correspondence should be addressed to Hao Xu, xuhaotcm@gmail.com
Received 24 November 2011; Accepted 26 January 2012
Academic Editor: Keji Chen
Copyright © 2012 J. Luo and H. Xu. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. The aim of this overview was to summarize the outcome measures of Chinese herbal medicine (CHM) as the treatment
of coronary heart disease (CHD) based on available systematic reviews (SRs),so as to display the current situation and evaluate the
potential beneﬁts and advantages of CHM on CHD. Methods. An extensive search included the Cochrane Database of Systematic
Reviews, MEDLINE, and 4 databases in Chinese. SRs of CHM for CHD were included. Besides evaluating and summarizing the
outcome measures, we also estimated the quality of the included reviews by PRISMA (preferred reporting items for systematic
reviews and meta-analyses). Data were extracted according to predeﬁned inclusion criteria by two independent reviewers. Results.
46 articles were included. 20 kinds of CHM were reviewed. 7 SRs were concerned with myocardial infarction (MI), 38 SRs were
related to angina pectoris. 11 SRs had primary endpoints, while others focused on secondary endpoints to evaluate CHM for CHD
such as angina pectoris and electrocardiogram (ECG). One SR reported more adverse eﬀects of CHM for CHD and of the SRs
analyzed quality of life. Many CHM appeared to have signiﬁcant eﬀect on improving symptoms, ECG, biomarkers and so on.
However, most SRs failed to make a deﬁnite conclusion for the eﬀectiveness of CHM in CHD patients due speciﬁcally to the poor
evidence. And according to PRISMA we found most of the trials in the SRs were of low quality. Conclusion. Primary endpoints
were not used widely. The beneﬁts of CHM for CHD need to be conﬁrmed in the future with RCTs of more persuasive primary
endpoints and high-quality SRs.
1.Introduction
Coronary heart disease (CHD) is the most common cause
of death in western countries. With the infectious diseases
controlledandimprovementofpeople’sliving,themorbidity
of CHD increases year by year in many developing countries.
Acute myocardial infarction (AMI) and angina pectoris are
the most important two types of CHD. Chinese herbal
medicine (CHM) has a 3000-year-old history with unique
theories for concepts of etiology and systems of diagnosis
and treatment [1]. The interest in CHM is growing rapidly
beyond China [2–5]. In recent years, some researchers
have reported the eﬀect of CHM on clinical symptoms,
biomarkers and mortality in CHD patients. However, the
evidence of CHM needs to be reviewed systematically and
appraised critically.
High-quality systematic reviews (SRs) of randomized
controlled trials (RCTs) are the sources of the best evidence
[6]. Currently, there is an increasing number of SRs on
studies of CHM, but few of them concluded that CHM was
deﬁnitely eﬀective for CHD due to the weak evidence. In
addition to rigorous clinical design and standard reporting,
the selection of outcome measures also plays an important
role in drawing a more persuasive conclusion. The aim of
this overview was to summarize the outcome measures of
CHM as the treatment of CHD based on available SRs, so
as to display the current situation and evaluate the potential
beneﬁts and advantages of CHM on CHD.
2. Methods
Electronic literature searches were performed to identify
the maximum possible number of systematic reviews/meta-
analyses of CHM for CHD. The following electronic
databases were searched: (1) The Cochrane Database of2 Evidence-Based Complementary and Alternative Medicine
SystematicReviews(Issue10of12,Oct2011);(2)MEDLINE
(2001 to 2011); (3) Chinese Biomedical Database (CBM,
2001 to 2011); (4) China National Knowledge Infrastructure
(CNKI, 2001 to 2011); (5) Wanfang Databases (2001 to
2011); (6) Chinese VIP Information (VIP, 2001 to 2011).
CBM, CNKI, Wanfang, and VIP were databases in Chinese.
We searched databases in Chinese because CHMs were
researched in china mostly. And we searched papers from
2001 to 2011 for high-quality RCTs and SRs mainly focusing
in recent ten years.
T h es t r a t e g yb e l o ww a su s e dt os e a r c hT h eC o c h r a n e
Library and adapted appropriately for use in diﬀerent
electronic bibliographic databases: #1 herb∗; #2 medic∗;
#3 (#1 and #2); #4 Chinese; #5 (#3 or #4); #6 cardiac; #7
heart; #8 circulation; #9 (#6 or #7 or #8); #10 (#5 and
#9). To determine which article was we want, we scanned
the title and abstract of each record independently by two
reviewers (J. Luo and H. Xu ). If the information included
a systematic review or a meta-analysis of CHM for CHD,
the full paper was obtained for further assessment. Papers
were excluded when problems occurred with: repeat pub-
lication; methodological studies; quality assessment report;
the interventions in the control groups were other Chinese
herbs; research on acupuncture, qigong, massage, or other
treatments (Figure 1).
We divided the outcome measures into primary end-
points and secondary endpoints [50, 51]. Primary endpoints
include the mortality, AMI, restenosis after percutaneous
coronary intervention (PCI), and recanalization. Secondary
endpoints mainly indicate surrogate endpoints and labora-
tory measures, which include angina pectoris, arrhythmia,
heart failure, consumption of nitroglycerine, electrocardio-
gram (ECG), ultrasonic cardiogram (UCG), Level of blood
lipids, plasma endothelin, nitric oxide, myocardial enzyme,
hemorheology, heart rate variability, and traditional Chinese
medicine (TCM) syndrome.
In addition, we used PRISMA (preferred reporting items
for systematic reviews and meta-analyses) as assessment
tool to estimate the quality of the included reviews. This
checklistincludes27itemsof7keyareas.Anditdescribesthe
preferredwaytopresenttheabstract,introduction,methods,
results, and discussion sections of a systematic review and
a meta-analysis paper. It requires authors of each review
to include a ﬂow diagram that provides information about
the number of studies identiﬁed, included, and excluded
and the reasons for excluding them [52]. Information on
each of the included reviews was imported into PRISMA
statement for analysis. All data were extracted independently
bytwoauthorsusingpredeﬁnedcriteria.Disagreementswere
resolved by discussion between the authors. All inconsisten-
cies were revised after a consensus was reached.
3. Results
46 articles were included (7 in English and 39 in Chinese).
39 SRs from the Chinese databases were published between
2004 and 2011. Since 2007, the number of SR increased
markedly. 5 SRs from the Cochrane Database were published
Potentially relevant publication
identiﬁed through search strategy:
Full articles retrieved for more
detailed evaluation:
Articles identiﬁed for inclusion 
in the review:
total =223
total =53
total =46
Articles excluded: duplicates;
nonclinical studies;
total =170
total =7
case reports; research on 
acupuncture, qigong, massage,
or other treatments:
Articles excluded:
Methodological studies: 1
Quality assessment report: 1
The interventions in the 
control groups were other 
Chinese herbs: 5
Figure 1: Flow-chart of SRs selection.
between 2006 to 2011 [8, 13, 26, 36, 44]. 2 SRs from
MEDLINE were published between 2006 to 2011 [14, 45].
7 SRs were concerned with myocardial infarction (MI),
38 SRs were related to angina pectoris, and one SR was
concerned with preventing and treating restenosis after PCI.
The trials in SRs were mainly originated from china. The
original trials included were called “RCTs” or “quasi-RCTs”,
b u to n l yaf e wo ft h e mw e r et y p i c a lR C T s .M o s to ft h e
trials in the SRs were of low quality, only 14 RCTs were
high quality: one was concerned with MI, 12 were related to
angina pectoris, and one was about preventing and treating
restenosis.
20 kinds of CHM were reviewed, including injections,
capsules, tablets, pellets, and herbal decoction as follows:
Danshen preparations (n = 13) [8, 14, 20–22, 33, 38–41, 45–
47], 7 of them were compound salvia pellet [14, 22, 33, 38,
45–47]; Tongxinluo Capsule (n = 4) [13, 22, 27, 37]; Yiqi
huoxue (supplementing qi and activating blood circulation)
products(n = 3)[10,32,49];Xuefuzhuyudecoction(n = 2)
[23, 30]; herbal products (n = 4) [11, 12, 17, 26]; Shengmai
injection (n = 2) [9, 24]; Suxiao jiuxin wan (n = 2) [35, 36];
Gingko (n = 2) [28, 29]; Acanthopanax (n = 2) [53, 54];
Puerarin (n = 2) [15, 44]; Shexiang baoxin wan (n = 2)
[34, 55]; Shenmai injection (n = 1) [7]; Tetramethylpyrazine
(n = 1) [43]; Shuxuetong (n = 1) [48]; Xinkeshu (n = 1)
[31]; Saﬄower injection (n = 1) [25]; Rhodiola (n = 1) [42];
Kudiezi injection (n = 1) [19]; Shuyu zaogan tablets (n = 1)
[18]; Dengzhanhua injection (n = 1) [16].
11 SRs analyzed primary endpoints and the others all
focused on secondary endpoints to evaluate CHM for CHD
(Table 1). This was mainly based on whether there were
available data in the original trials or not. Four primary
endpoints were analyzed in the SRs including mortality,
nonfatal myocardial infarction, restenosis after PCI, and
recanalization. None of these SRs analyzed the quality of life.
Angina pectoris was the most common secondary endpoint
in the SRs. There was one SR without clear outcome
measures [53] ,a n d2S R so n l yu s e d“ m a r k e de ﬀective,”
“eﬀective,”“ineﬀective” as comprehensive outcome measures
involving symptoms improvement and ECG changes [19,
54]. Many CHMs appear to have signiﬁcant eﬀect on
improving symptoms, ECG, and level of blood lipids andEvidence-Based Complementary and Alternative Medicine 3
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reducing the consumption of nitroglycerine, and so forth.
Some SRs also reﬂected that CHM may be eﬀective to reduce
the risk of subsequent MI, heart failure, and arrhythmia.
However, most SRs failed to draw a deﬁnite conclusion of the
eﬀectiveness of CHM for CHD due speciﬁcally to the poor
evidence.
Adverse eﬀects, which are important when evaluate
a medicine, should be regarded as an essential outcome
measure in clinical trials. However, only a few of the trials
in the SRs had long-term data on adverse eﬀects. Most of
adverse eﬀects of CHM were mentioned as “low adverse
eﬀect” or “none obvious”. The adverse events reported
majorly were abdominal complaints, nausea, and dyspepsia.
One review reported more adverse reactions in treatment
groups than in control groups [44]. Recently, several reviews
have highlighted adverse reactions of CHM [56, 57].
Compared the usage of outcome measures between
Cochrane and non-Cochrane reviews, we found that out-
come measures of the included papers in Cochrane are
more comprehensive. Every Cochrane review took primary
endpoints, secondary endpoints, and safety as outcome
measures.However,primaryendpointsandsafetyareseldom
taken as outcome measures in most of the non-Cochrane
reviews. None of reviews analyzed quality of life or pay
attention to medical economics.
According to PRISMA statement, we found that most of
the included reviews are of low quality. The deﬁciencies are
as follows: review methods in the abstracts and rationales
for review were not well reported; only about half of the
SRs reported the characteristics of included trials; just 5 SRs
provided ﬂow chart in the article, 2 in Chinese [22, 29], and
3 in English [8, 14, 26]; potential biases were not described
well in the reports; most SRs lack in persuasive outcome
measures.
4. Discussion
Our overview shows that primary endpoints and secondary
endpointsareallusedtoevaluatetheeﬀectofCHMforCHD.
Secondary endpoints are most commonly adopted in clinical
trials due to their feasibility in small sample size and short-
term clinical trials. They may signify future cardiovascular
e v e n tt os o m ee x t e n ta n da r es u r et ob ev a l u a b l ea ss u r r o g a t e
endpoints. But it is clearly that primary endpoints are more
persuasive in RCT of cardiovascular diseases. However, most
of the outcome measures in the included SRs are angina
pectoris and ECG. Primary endpoints such as mortality and
major cardiovascular events are not used widely. Adverse
eﬀects, quality of life, and medical economics, which are
also important when evaluate a medicine, should be taken
as outcome measures too. All of these are the reasons why
neither the trials nor the SRs of CHM for CHD could meet
as u ﬃciently high standard to be broadly accepted by the
Western medical community.
SRs of CHM with poor methodology and reporting
quality have been reported [58]. According to PRISMA
statement, we found that most of the included reviews have
poor quality. Reviewers were not good at reporting how they
avoided bias in selecting primary studies, how they extracted
data, and how they evaluated the validity of the primary
studies. Also, most of the reviewers chose less persuasive
outcome measures, which reduced the persuasion of the
interventions. So if reviewers did not master the method of
performing SR, they could produce inaccurate or misleading
conclusions for current clinical practice and even the future
research. Although it appeared that CHM was eﬀective
for CHD in clinical use, such as compound salvia pellet,
shengmai injection, suxiao jiuxin wan, and gingko, puerarin,
most SRs were inconclusive that CHM had a deﬁnite eﬀect
for CHD owing to the poor evidence.
Before recommending the conclusion, we have to con-
sider the following weaknesses in this overview. Firstly, data
were abstracted from SRs instead of the original trials,
and most of the included SRs have poor quality. Secondly,
most of the RCTs in the SRs included are also of low
quality due mainly to unclear randomization and blinding
method, incomplete outcome reporting, publication bias,
and so forth. Thirdly, we only selected SRs published in
Chinese and English. SRs of CHM for CHD published in
other language or originated from other countries might be
omitted. Fourthly, we did not identify unpublished studies,
thus negative trial might not be reported and could induce
publication bias.
In conclusion, primary and secondary endpoints were
all used to evaluate the eﬀectiveness of CHM for CHD,
but primary endpoints were not used widely. Although it
appeared that CHM was eﬀective for CHD in terms of
some outcome measures, most SRs failed to draw a deﬁnite
conclusion for the eﬀectiveness of CHM in CHD patients
due to the poor evidence. The beneﬁts of CHM for CHD
still need to be conﬁrmed in the future with RCTs of more
persuasive primary endpoints and high-quality SRs.
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